Efficacy and safety of onabotulinum toxin A for overactive bladder  

作　　者：Chintan K Patel Arthur P Mourtzinos 

机构地区：[1]Institute of Urology,Lahey Hospital and Medical Center

出　　处：《World Journal of Clinical Urology》2016年第2期75-79,共5页世界临床泌尿杂志

摘　　要：Overactive bladder(OAB) syndrome is a condition which affects 16.9% of women and 16.2% of men with a significant negative impact on quality of life. It is a condition characterized by urgency, with or without urge incontinence, frequency and nocturia. Behavioral modifications and oral anti-muscurinic medications are first and second-line therapies for OAB but are frequently ineffective or poorly tolerated. For refractory cases of OAB, onabotulinum toxin can be offered and this therapy was approved by the Food and Drug Administration in January of 2013. In this editorial, we will review the indications, usage, efficacy and safety data for intradetrusor injection of onabotulinum toxin A.Overactive bladder(OAB) syndrome is a condition which affects 16.9% of women and 16.2% of men with a significant negative impact on quality of life. It is a condition characterized by urgency, with or without urge incontinence, frequency and nocturia. Behavioral modifications and oral anti-muscurinic medications are first and second-line therapies for OAB but are frequently ineffective or poorly tolerated. For refractory cases of OAB, onabotulinum toxin can be offered and this therapy was approved by the Food and Drug Administration in January of 2013. In this editorial, we will review the indications, usage, efficacy and safety data for intradetrusor injection of onabotulinum toxin A.

关 键 词：Onabotulinum toxin A BOTOX OVERACTIVE BLADDER OVERACTIVE BLADDER NEUROGENIC BLADDER Urinary BLADDER DETRUSOR OVERACTIVITY 

分 类 号：R[医药卫生]